论文部分内容阅读
目的:探讨使用替吉奥单药医治胃癌术后患者的疗效。方法:将46例胃癌术后患者进行随机分组,对照组和实验组各23例。对照组给予卡培他滨进行化疗,实验组则给予替吉奥单药进行医治,将两组患者的治疗效果进行对比观察。结果:实验组患者治疗后的1年生存率和无复发生存率分别为69.6%和52.2%,和对照组比较,差异不明显(P>0.05)。实验组患者进行治疗后发生的毒副作用较对照组小,但差异无统计学意义(P>0.05)。结论:替吉奥单药治疗胃癌术后患者的治疗效果不低于卡培他滨,且患者发生的毒副作用较小,是临床医治胃癌术后患者的理想方案之一。
Objective: To investigate the efficacy of using Giotin for treating postoperative patients with gastric cancer. Methods: 46 cases of gastric cancer patients were randomly divided into control group and experimental group of 23 cases. The control group was given capecitabine for chemotherapy, while the experimental group was given the drug for treatment of Giotto, and the therapeutic effects of the two groups were compared. Results: The 1-year survival rate and recurrence-free survival rate of the experimental group were 69.6% and 52.2%, respectively, which were not significantly different from those of the control group (P> 0.05). The toxicities and side effects of experimental group patients after treatment were smaller than that of the control group, but the difference was not statistically significant (P> 0.05). CONCLUSION: Therapeutic effect of TEGO monotherapy in postoperative patients with gastric cancer is not less than that of capecitabine, and the patients have less side effects. It is one of the ideal options for clinical treatment of postoperative patients with gastric cancer.